EN
中文
EN
Who We Are
Newsroom
Innovation
Products
Investor Relations
Careers
Contact Us
Information Disclosure
Home
>
Investor Relations
>
Information Disclosure
H Share
2019 ANNUAL REPORT
INSIDE INFORMATION RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR) APPROVED FOR CLINICAL TRIAL
INSIDE INFORMATION
NOTICE OF BOARD MEETING
INSIDE INFORMATION PRE-IND REVIEW APPLICATION FOR RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR) AND LAUNCH OF PRE-SCREENING OF HEALTHY VOLUNTEERS
Monthly Return of Equity Issuer on Movements in Securities
Monthly Return of Equity Issuer on Movements in Securities
INSIDE INFORMATION DEVELOPMENT OF COVID-19 VACCINE CANDIDATE
ANNOUNCEMENT ACCEPTANCE BY THE SHANGHAI STOCK EXCHANGE OF APPLICATION MATERIALS FOR THE PROPOSED ISSUE OF A SHARES
INSIDE INFORMATION FINANCIAL INFORMATION IN RELATION TO A SHARE PROSPECTUS
1
41
42
43
44
45
49
津公网安备12011602300399
